ACS Appl Bio Mater. 2019 Jun 17;2(6):2444-2452. doi: 10.1021/acsabm.9b00156. Epub 2019 May 15. Bone Marrow Mesenchymal Stem Cells Encapsulated in a Hydrogel System via Bioorthogonal Chemistry for Liver Regeneration Yajie Zhang, Yue Zan, Hong Chen, Zhili Wang, Tianyu Ni, Min Liu, Renjun Pei Abstract Liver tissue engineering is going to be an effective treatment for end-stage liver disease. In this work, we distributed bone marrow mesenchymal stem cells (BMSCs) into a fast-forming hydrogel system to develop a liver-mimicking construct for liver regeneration. The advantage of this hydrogel system was that this BMSC-encapsulating hydrogel could be formed via a bioorthogonal reaction between 2-cyanobenzothiazole and cysteine within several seconds. Thereafter, we explored the morphology, biocompatibility, and expressions of hepatic differentiation markers of this hydrogel system. These results illustrated that this system could provide a suitable niche for BMSC proliferation and differentiation, which could aid in future biomedical research of liver regeneration. Keywords: BMSC-encapsulating; bioorthogonal reaction; fast-forming hydrogel; liver regeneration; tissue engineering. Related products Abbreviation: 4-arm PEG-NH2 Name: 4-arm Poly(ethylene glycol) amine Abbreviation: 4-arm PEG-CM Name: 4-arm Poly(ethylene glycol) carboxylic acid For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com

Colloids Surf B Biointerfaces. 2016 Sep 1;145:785-794. doi: 10.1016/j.colsurfb.2016.05.074. Epub 2016 May 27. Efficient nanobiocatalytic systems of nuclease P1 immobilized on PEG-NH2 modified graphene oxide: effects of interface property heterogeneity Wei Zhuang, Linjiao He, Jiahua Zhu, Jianwei Zheng, Xiaojing Liu, Yihui Dong, Jinglan Wu, Jingwei Zhou, Yong Chen, Hanjie Ying Abstract The use of graphene oxide (GO) nanosheets for functional enzyme support has attracted intensive interest owing to their unique planar structure and intriguing physical and chemical properties. However, the detailed effects of the interface properties of GO and its functionalized derivatives on active biomolecules are not well understood. We immobilize nuclease P1, a common industrial nucleic acid production enzyme, on pristine and amino poly(ethylene glycol) (PEG-NH2) modified GO nanosheets with interface property heterogeneity using two approaches, physical adsorption and chemical crosslinking. It is demonstrated that nuclease P1 could be stable immobilized on the surface of pristine GO by physical adsorption and on the edge of modified GO nanosheets by chemical crosslinking. The resultant loading capacity of nuclease P1 on pristine GO is as high as 6.45mg/mg as a consequence of strong electrostatic and hydrophobic interactions between the enzyme and carrier. However, it is determined that the acid resistance, thermal stability, reusability and degradation efficiency of the immobilized enzyme on PEG-NH2-modified GO are obviously improved compared to those of the enzyme immobilized on pristine GO. The enhanced catalytic behavior demonstrates that GO and its derivatives have great potential in efficient biocatalytic systems. Keywords: Enzyme immobilization; Graphene oxide; Interface; Modification; Nuclease P(1). Related products Abbreviation: 4-arm PEG-NH2 Name: 4-arm Poly (ethylene glycol) amine For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com

ACS Omega. 2018 Feb 28;3(2):2396-2405. doi: 10.1021/acsomega.7b02022. Epub 2018 Feb 27. Combined Adsorption and Covalent Linking of Paclitaxel on Functionalized Nano-Graphene Oxide for Inhibiting Cancer Cells Wei Zhuang, Linjiao He, Kai Wang, Bo Ma, Lei Ge, Zhenfu Wang, Jinsha Huang, Jinglan Wu, Qi Zhang, Hanjie Ying Abstract Developing targeted delivery nanosystems for delivering chemotherapeutic anticancer drugs specifically to cancerous tissues with improvement in the specificity of drugs for different cancer cells can result in high therapeutic efficacy and low toxicity in healthy tissues. Herein, we proposed the synthesis of a multifunctional nanodelivery system, folic acid (FA) decorating nanographene oxide (nGO) functionalized with poly(ethylene glycol) (PEG), called pGO-FA, with good biocompatibility and good delivering performance of a hydrophobic water-insoluble anticancer drug of paclitaxel (PTX). 4-br-PEG-NH2, FA, and PTX were attached to PEG-functionalized nGO (pGO) through a combined chemical and physical force to form a nanosized complex, pGO-FA-PTX, defined as the nanodrug system. WST-8 assay in vitro illustrated that pGO-FA-PTX inhibited A2780 cells in a concentration-dependent manner. Cell viability was kept high to 60% when treated with 200 nM of free PTX. However, pGO-FA-PTX with the same dose of PTX (cell viability less than 30%) had double the cytotoxicity effect compared to free PTX. Furthermore, fluorescence observation demonstrated that pGO-FA-PTX exhibited an improved efficiency in killing A2780 cells due to the special affinity between FA and FA receptor, which has high expression in cancer cells. The strategy and method used in this study could be effective in improving both the bioavailability of PTX and therapy efficiency. Related products Abbreviation: 4-arm PEG-NH2 Name: 4-arm Poly(ethylene glycol) amine For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com

Langmuir. 2020 Feb 11;36(5):1235-1240. doi: 10.1021/acs.langmuir.9b03325. Epub 2020 Jan 27. Host-Guest Interactions between Oxaliplatin and Cucurbit[7]uril/Cucurbit[7]uril Derivatives under Pseudo-Physiological Conditions Han Wu, Hao Chen, Bohan Tang, Yuetong Kang, Jiang-Fei Xu, Xi Zhang Abstract Compared with conventional drug delivery systems (DDSs), DDSs based on host-guest interactions possess unique advantages, such as high selectivity, tunable binding ability, and controllable release of drugs. It is important to study the host-guest interactions between the carrier and drug under physiological conditions for constructing DDSs. In this work, we have studied the host-guest interaction between cucurbit[7]uril (CB[7]) and oxaliplatin (OxPt), a clinical antitumor drug, in the cell culture medium. The results show that amino acids such as phenylalanine in the 1640 culture medium can partially occupy the cavity of CB[7], which leads to the decrease of enthalpy changes of the host-guest interaction between OxPt and CB[7]. In addition, inorganic salts such as NaCl in the medium reduce the enthalpy change and increase the entropy change of the binding because of the preorganization of the portal of CB[7] and sodium cation. As a result, the binding constant of CB[7] with OxPt in the 1640 culture medium is 1/20 of that in pure water. When CB[7] is modified at the terminal of star-type PEG to construct the star-PEGylated CB[7], it is shown that the molecular weight and topological structure of the PEG polymer backbone exhibit little effect on the host-guest interactions between CB[7] and OxPt. This study enriches the host-guest chemistry of cucurbiturils and may provide guidance for constructing novel DDSs based on host-guest interactions with high loading and releasing efficiency. Related products Abbreviation: 2-arm PEG-N3 (PT02) Name: 2-arm Methoxypoly (ethylene glycol) azide (PT02) For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com

LNP formulations usually have between 35-45% composition with respect to cholesterol. Cholesterol is a derivative of cyclopentane polyhydrophenanthrene, which is widely present in animals. Cholesterol is involved in the formation of cell membranes and is an indispensable and important substance in animal tissue cells. Traditionally, cholesterol is derived from animals, mainly from the saponification of the brain and vertebral tendons of pigs, cattle and sheep, or lanolin, which is extracted using organic solvents. Since many diseases are now found to be transmitted from animals to humans, according to the latest guidelines for cell therapy and gene therapy, animal-derived ingredients should be avoided and a safer source of cholesterol is needed. SINOPEG's plant-derived cholesterol is synthesized through biosynthesis technology using plant extracts as the initial raw material. The product has no animal origin and meets the guidelines for cell therapy and gene therapy with high safety and clear composition. The product is a pure plant-derived biosynthetic cholesterol with no animal-derived components. It is less risky compared to traditional lanolin, pig, and cow products of animal origin. Plant-derived cholesterol is well suited for applications in the preparation of lipid nanoparticle (LNP) delivery systems, in the development of mRNA vaccines, in cell culture, serum-free cell culture for protein drugs, and other high-technology drug researches. Plant-derived cholesterol can also be used as a key raw material for the synthesis of vitamin D and its derivatives. The typical application includes such as in small unilamellar vesicles’ preparation, in the preparation of small unilamellar vesicles for structured illumination microscopy studies, in the generation of thymoquinone (TQ) loaded liposomes for administering into murine model with Candida albicans infection. Lipids for LNPs DHA (ALC-0315) mPEG-DTA (ALC-0159) HUO (SM-102) mPEG-DMG DSPC DOPE Cholesterol (Plant) R-DODMA R-DOTMA-Cl Dlin-MC3-DMA DOTAP DOTAP-Cl mPEG-DSG mPEG-C-DMG DSPE-PEG-MAL For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com

Cell & Gene Therapy Bioprocessing & Commercialization is the most focused event for cost effective and efficient cell, gene and immunotherapy approaches. CGT delivers the focused science and business content designed specifically for the cell therapy and regenerative medicine fields, while providing a pivotal gathering place for connecting industry, funding sources, government and academia. Welcome to visit us at SINOPEG's Booth#104at CGT, Boston Convention and Exhibition Center, USA from 27th to 30th September. https://informaconnect.com/cell-therapy-bioprocessing/ #event #CGT #Boston SINOPEG is a dynamic science company with professional R&D, Manufacturing and Sales capability. The company is mainly engaged in drug delivery system (DDS) and new medical materials business. Founded in 2011, SINOPEG has a team of highly qualified and science background employee personnel. We devote ourselves to research, develop and produce high quality Polyethylene glycol, Polyethylene glycol derivatives, Block copolymers, Anti-diabetic drug side chains, lipids for LNPs, GalNAc conjugates, ADC and ProTAC Linker, etc. Please contact us at sales@sinopeg.com 

#ASOs #antisense oligonucleotide #GalNAc #drug delivery #ligand targeting   Drug development scheme using the GalNAc conjugate, is better suited for selecting BNA-based ASOs, especially for the treatment of liver-associated diseases.   gnitude   https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(22)00428-2   Antisense oligonucleotides (ASOs) containing bridged nucleic acids (BNAs) have been proven to be very powerful. However, there is still a challenge to ensure a reliable discovery and translational development scheme for this class of ASOs with wider therapeutic windows. The robustness of the scheme was demonstrated in the context of the selection of ASOs, which have two different BNA chemistries (2,′4′-BNA/locked nucleic acid [LNA] and amido-bridged nucleic acid [AmNA]) targeting human proprotein convertase subtilisin/kexin type 9 (PCSK9). A two-step process was shemed, including a unique and sensitive in vitro screening approach, called Ca2+ enrichment of medium (CEM) transfection, and a ligand-targeted drug delivery approach to better reach target tissues, averting unintended accumulation of ASOs. An N-acetylgalactosamine (GalNAc) ligand then was appended to the candidate ASO to further broaden the therapeutic margin by altering the molecule’s pharmacokinetics. With reduced nephrotoxicity in rats, the GalNAc conjugate, HsPCSK9-1811-LNA, was found to be at least ten times more potent in non-human primates. Overall, a drug development scheme was shown better suited for selecting clinically relevant BNA-based ASOs, especially for the treatment of liver-associated diseases.

Bagsværd, Denmark , 2 2 August 2022 – Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema, a once-weekly subcutaneous combination of semaglutide and a novel amylin analogue, cagrilintide. The trial investigated the efficacy and safety of a fixed dose combination of CagriSema (2.4 mg semaglutide and 2.4 mg cagrilintide) compared to the individual components semaglutide 2.4 mg and cagrilintide 2.4 mg, all administered once weekly, in 92 people with type 2 diabetes and overweight. People were equally randomised among the three treatment arms. In the trial, the mean baseline HbA1c was 8.4% and the mean baseline body weight was 106 kg. After 32 weeks of treatment, people treated with CagriSema achieved a numerically higher HbA1c reduction of 2.18%-points compared to a reduction of 1.79%-points for people treated with semaglutide and 0.93%-points with cagrilintide alone. People treated with CagriSema achieved a numerically higher body weight reduction of 15.6% compared to a reduction of 5.1% for people treated with semaglutide and 8.1% with cagrilintide alone1. In the trial, CagriSema appeared to have a safe and well-tolerated profile. “We are encouraged by the impressive phase 2 results for CagriSema in people with type 2 diabetes,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk. “The results indicate that CagriSema reduces blood sugar more than semaglutide alone and the weight loss seen in the trial confirms the substantial weight lowering potential of CagriSema”. Based on the results, Novo Nordisk is now planning to initiate a phase 3 development programme for CagriSema in people with type 2 diabetes in 2023. The CagriSema (2.4 mg semaglutide and 2.4 mg cagrilintide) phase 3 programme in people with overweight and obesity, REDEFINE, is expected to begin in the fourth quarter of 2022. Source:  https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=131155